Core Viewpoint - The company, Tianchen International Medical Technology Co., Ltd., has adjusted the upper limit of its share repurchase price following the implementation of its 2025 semi-annual equity distribution, reducing it from RMB 28.53 per share to RMB 28.03 per share, effective from October 16, 2025 [2][10]. Summary by Sections Share Repurchase Overview - On December 27, 2023, the company approved a share repurchase plan with a total fund of no less than RMB 18 million and no more than RMB 36 million, with a maximum repurchase price of RMB 30.00 per share, valid for 12 months [3][15]. - On July 9, 2024, the company increased the repurchase fund to a range of RMB 36 million to RMB 72 million, reflecting confidence in its future development [4][16]. - On December 25, 2024, the repurchase fund was further adjusted to between RMB 46 million and RMB 80 million, extending the repurchase period to December 26, 2025 [6][17]. Adjustment of Repurchase Price Limit - Following the 2025 semi-annual equity distribution, the repurchase price limit was adjusted from RMB 30.00 to RMB 29.51 per share [5]. - After the special dividend distribution in January 2025, the price limit was further adjusted to RMB 28.53 per share [8]. - The final adjustment post the 2025 semi-annual equity distribution set the price limit at RMB 28.03 per share, calculated based on the cash dividend of approximately RMB 0.4970 per share [10][11]. Repurchase Progress - As of September 30, 2025, the company had repurchased a total of 2,505,324 shares, representing 3.09% of its total share capital, with a total expenditure of approximately RMB 42.5 million [19].
天臣国际医疗科技股份有限公司关于2025年半年度权益分派实施后调整回购股份价格上限的公告